Gilead Sciences (NASDAQ: GILD) is one of the largest bio-pharmaceutical companies in the world with a market capitalization of roughly $90 billion. The company has performed admirably well since the start of the year due to investor excitement over Remdesivir, a potential COVID-19 treatment. On top of this, the remainder of the company's portfolio has continued to perform incredibly well leading to a strong overall portfolio.
Gilead Sciences - Capital Street FX
Gilead Sciences Filgotinib
Gilead Sciences has recently announced strong results from its Filgotinib portfolio of drugs it is working on with Galapagos